Mihrican Koçak1, Özüm Atasoy2, Nilsu Çini2, Oytun Erbaş1,3

1Institute of Experimental Medicine, Kocaeli, Turkey
2Department of Radiation Oncology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey
3Department of Physiology, Demiroglu Science University, Faculty of Medicine, Istanbul, Turkey

Keywords: Glioblastoma, isocitrate dehydrogenase, O6-methylguanine-DNA methyltransferase.


Glioblastoma is the most aggressive primary malignant brain tumor, also known as isocitrate dehydrogenase (IDH) wild-type gliomas. Symptoms vary depending on where the tumor is located. It is often manifested by headaches, epileptic seizures, and personality changes. Glioblastoma constitutes 15% of primary brain tumors and the reasons for its formation are still unclear. Primary treatment is surgery, followed by chemoradiotherapy. Although maximal surgical resection is standard, it often recurs. The vast majority of patients die within two years of diagnosis. In this study, we aimed to examine glioblastoma in detail with the treatment possibilities available today.

Conflict of Interest

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Financial Disclosure

The authors received no financial support for the research and/or authorship of this article.